secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001564590-22-029394
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double
--------------------------------------------------------------------------------

- Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.
- ANNOVERA revenue $18.3M, up 91% YoY; 9,329 TRx (+28% YoY); over 13,000 prescribing HCPs (+65%).
- Operating expenses fell 21% to $42.7M; debt reduced to $90.8M after repaying $125M in 2022.
- Cash $26.3M plus $11.3M restricted; vitaCare divestiture gain $143.4M.
- FDA approved sNDA for ANNOVERA; CEO highlights focus on women's health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/0001564590-22-029394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/txmd-8k_20220815.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-029394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer